Study on newly-identified cannabinoid to produce new therapies

535 0

The cannabimovone cannabinoid is similar to CBD, but with specific healing traits

The research to understand and discover all components of the cannabis plant continue, and a new study exposes a recently discovered cannabinoid that can lead to the creation of powerful therapies in the future. The cannabinoid is called cannabimovone (CBM), and it is a cousin of one more popular compound in the cannabis plant, cannabidiol (CBD). According to research, CMB occurs naturally within the hemp plant and, although it hasn’t been studied that much yet, it seems to have benefits as a treatment for diabetes, metabolic syndromes and eating disorders.

The study was published this month in Molecules, and it was done by researchers in Italy along with the Institute of Biomolecular Chemistry, the National Research Council, the Italy Endocannabinoid Research Group and the University of Naples. Through the use of 3D modeling, it was discovered that CBM can cohere to human receptors, specifically two key receptor types – including the two PPAR receptors, PPARα and PPARy, PPAR (peroxisome proliferator-activated receptor). These receptors participate in the body’s general homeostasis and the lipids metabolism therefore they play a significant role in the overall energy levels and fat burning process. Also, these PPAR receptors have control over the genes that create new cells on major organs such as spleen, colon, heart, kidneys, liver and the pancreas.

“Altogether, these results candidate CBM as a novel bioactive compound potentially useful for the treatment of insulin resistance‐related disorders,” said the study. Adding that further research could confirm CBM as an “anti-diabetic and insulin-sensitizing drug,” opening the doors for new therapeutic alternatives for patients who haven’t found an effective treatment yet.